Research Objectives: Evaluation of the potential protective effect of Vitamin D in doxorubucin- induced toxicity in breast cancer patients.~Proposal Steps:~Assessing breast cancer patients taking part in the study receiving adjuvant chemotherapy AC (Anthracycline (Doxorubucin)-cyclophosphamide) for breast cancer for 4 cycles every 21 day (i.e. 3 months.)~100 Patients are randomly assigned in to two groups:~Control group (n=50) the patient will receive AC regimen (Doxorubucin & Cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)~Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin D once daily.~All participants are recruited from AMUH Hospital Oncology Unit. All participants will be given their consent. The study will be approved by research ethics committee of Damanhour University.~Tumor staging is done according to American joint committee on cancer (TNM staging of breast cancer eighth edition (Amin et al., 2017).~All patients will be submitted to:~Full patient history and clinical examination.~Routine follow up before and after each chemotherapy cycle (complete blood picture, liver function tests, renal function tests.~Echocardiography (Echo) at base line and at the end of the treatment.~Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end of the study.~Methodology:~Venous blood samples will be analyzed using ELISA Vitamin D, IL-6 kits and immuno-histo-chemistry Troponoin-T and LDH and kits.
The study is aimed at Evaluation of the potential protective effect of Vitamin D in doxorubucin- induced toxicity in breast cancer patients.~Proposal Steps:~100 Patients recruited from Alexandria Main University Hospital (AMUH), Oncology Unit are randomly assigned in to two groups:~Control group (n=50) the patient will receive AC regimen (Doxorubucin & cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)~Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin D (Bon One 0.5 microgram®) once daily.~Echocardiography (Echo) will be done at base line and at the end of the treatment.~Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end of the study.